Compare · DFTX vs HAPP
DFTX vs HAPP
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Happiness Development Group Limited (HAPP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and HAPP operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.71B, about 315.9x HAPP ($14.9M).
- DFTX has hit the wire 7 times in the past 4 weeks while HAPP has been quiet.
- DFTX has more recent analyst coverage (5 ratings vs 0 for HAPP).
- Company
- Definium Therapeutics Inc.
- Happiness Development Group Limited
- Price
- $43.14+0.54%
- $4.52-2.80%
- Market cap
- $4.71B
- $14.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 0
- Recent ratings
- 5
- 0
Happiness Development Group Limited
Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. Happiness Biotech Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
Latest HAPP
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form EFFECT filed by Happiness Development Group Limited
- SEC Form F-3 filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form SC 13G filed by Happiness Development Group Limited
- SEC Form SC 13G filed by Happiness Development Group Limited
- SEC Form 20-F/A filed by Happiness Development Group Limited (Amendment)
- SEC Form 6-K filed by Happiness Development Group Limited